Brain cancer vaccine trial combines custom peptides with electric fields
NCT ID NCT03223103
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a personalized vaccine made from each patient's tumor mutations, combined with Tumor Treating Fields (a device that sends electric fields to the brain), is safe and feasible for people with newly diagnosed glioblastoma. The 13 participants receive the vaccine alongside standard care. The main goals are to check for side effects and see if the vaccine can be successfully made and given.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized mutation-derived tumor vaccine (peptides) plus Poly-ICLC (Hiltonol) and Tumor Treating Fields (Optune device)
What this could lead to
If successful, this could point toward a new way to treat glioblastoma by combining a personalized vaccine with standard care to help the immune system target the tumor.
What could go wrong
This is a very early (Phase 1) and small (13 people) trial focused on safety, not effectiveness. The vaccine is custom-made for each patient, which is complex and may not work for everyone. There is also a risk of side effects from the vaccine or device.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albert Einstein College of Medicine
The Bronx, New York, 10461, United States